Swiss firm BioVersys signs deal with Shionogi for antibiotics research

Swiss biotech firm BioVersys has signed a research and licensing agreement with the Japanese pharmaceutical company Shionogi. +Get the most important news from Switzerland in your inbox Under the terms of the collaboration, BioVersys is entitled to upfront and short-term research payments of CHF5 million, as the Basel-based company announced on Wednesday. Should Shionogi exercise a license option, approval and sales-based payments of up to CHF479 million ($604 million) tiered royalties on future sales would be added.